The FDA approved Celcuity’s Revtorpyk (gedatolisib) in a subset of patients with HR-positive/HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation, following progression on at least one line of endocrine therapy. The approval positions Revtorpyk as a PAM pathway inhibitor for patients with limited targeted options. Celcuity disclosed that the launch timing and early commercial rollout will be closely watched by investors, and some market participants reacted to an expected delay in commercialization even after the positive regulatory outcome. The drug’s approval includes use in combination regimens, and Celcuity has also signaled further regulatory strategy across additional settings. For pharma rivals, the clearance introduces a new mechanism into a competitive pathway space shaped by PI3K and related signaling inhibition strategies.